{"nctId":"NCT01931150","briefTitle":"Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT","startDateStruct":{"date":"2013-08"},"conditions":["Cetuximab-induced Papulopustular (Acneiform) Rash Who Have","Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma"],"count":11,"armGroups":[{"label":"Dapsone LEFT, Moisturizer RIGHT","type":"EXPERIMENTAL","interventionNames":["Drug: Topical Dapsone 5% Gel","Other: Moisturizer","Drug: oral antibiotics"]},{"label":"Dapsone RIGHT, Moisturizer LEFT","type":"EXPERIMENTAL","interventionNames":["Drug: Topical Dapsone 5% Gel","Other: Moisturizer","Drug: oral antibiotics"]}],"interventions":[{"name":"Topical Dapsone 5% Gel","otherNames":[]},{"name":"Moisturizer","otherNames":[]},{"name":"oral antibiotics","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients 18 years or older with underlying diagnosis of metastatic colorectal cancer or head and neck squamous cell carcinoma including newly diagnosed patient\n* Patients must provide written informed consent to participate in the study\n* Anticipated initiation of cetuximab treatment with or without additional chemotherapy.\n* Able to self-administer topical interventions or provide for another person to apply the topical interventions\n\nExclusion Criteria:\n\n* Females of childbearing potential who are pregnant or nursing\n* Patients with allergy, hypersensitivity or other contraindication to dapsone, sulfa antibiotics, or excipients of the dapsone gel product\n* Patients with pre-existing dermatologic condition affecting the face and chest that would impair assessment of papulopustular rash including dense and/or long facial hair (per investigator discretion)\n* Patients currently using prescription and/or over-the-counter topical medications to the face and/or chest who are unwilling to discontinue use during the trial intervention period (day 0 ± 2 days through day 28 ± 2 days)\n* Previous or concurrent radiation therapy to head, neck, and chest (i.e. application sites only)\n* Previous therapy with cetuximab within 6 months of consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients in Which the PI Observed a Notable Difference in the Number of Lesions","description":"Change from Baseline in the Number of Lesions at 28 days","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":5},"commonTop":[]}}}